This is a demo store. No orders will be fulfilled.

CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) - Primary antibody, specific to MAGEA3, Human IgG1

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human,Mouse
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab209920
Grouped product items
SKU Size
Availability
Price Qty
Ab209920-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$109.90
Ab209920-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$509.90
Ab209920-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,399.90
Ab209920-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,299.90

Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) - Primary antibody, specific to MAGEA3, Human IgG1
Synonyms Antigen MZ2 D antibody | Antigen MZ2-D antibody | Cancer/testis antigen 1.3 antibody | Cancer/testis antigen family 1 member 3 antibody | CT1.3 antibody | HIP8 antibody | HYPD antibody | MAGA3_HUMAN antibody | MAGE 3 antigen antibody | MAGE family member
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Biochemical and Physiological Mechanisms Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or sta
Host species Human
Specificity MAGEA3
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Product Description

CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment.

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 150 kDa
Purification Method Protein A purified
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Associated Targets(Human)

MAGEA3 Tbio Melanoma-associated antigen 3 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) (Ab209920) - Flow Cytometry
Flow Cytometry analysis of HCC1428 cells labelling MAGEA3 at 1×105 cell/well can bind CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) (Ab209920).

CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) (Ab209920) - SEC
The purity of CT Atlantic patent anti-MAGEA3 (anti-MAGEA3) (Ab209920) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.